Bradley Sumrall, MD
Medical Oncology · Macon, GANPI 1679689301
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $25,663 of the $35,784 with a category attached, or 71.7%. It is spread thinly across 58 manufacturers, the largest accounting for just 23.0%. Reporting peaked in 2021 at $10,012 and has fallen 52.1% since, to $4,793 in 2025.
Across 395 payments — averaging $90.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- Gilead$7K
- Amgen$3K
- Johnson & Johnson$3K
- Eisai Inc.$2K
- Seagen Inc.$2K
- plus $12K from 52 others
Across 51 payments — averaging $4649.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$116K
- Eli Lilly$50K
- Genentech, Inc.$44K
- Mirati Therapeutics, Inc.$23K
- E.r. Squibb & Sons, L.L.C.$3K
- F. Hoffmann-la Roche AG$3K
What the payments were for
- Consulting fees$25,66372%
- Speaking & faculty fees$1,6104%
- Travel & lodging$7842%
- Food & beverage$7,22220%
- Education$5051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,784 in reported general payments places this provider in the 85th percentile of 68 medical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 71 | $1,045,592 |
| PomalystPomalidomide | 21 | $480,336 |
| CabometyxCabozantinib S-Malate | 15 | $364,440 |
| TagrissoOsimertinib Mesylate | 19 | $345,571 |
| RevlimidLenalidomide | 13 | $230,402 |
| SprycelDasatinib | 15 | $173,759 |
| Abiraterone Acetate | 103 | $167,625 |
| BrukinsaZanubrutinib | 11 | $165,783 |
| Lenalidomide | 12 | $163,811 |
| EliquisApixaban | 113 | $87,724 |
| Imatinib Mesylate | 26 | $45,643 |
| Oxycodone Hcl | 210 | $4,184 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 156 | $3,058 |
| Morphine Sulfate ErMorphine Sulfate | 69 | $1,953 |
| Anastrozole | 203 | $1,921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $390 | $1,045,59271 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $115 | $654,09536 claims |
| Exelixis Inc.Cabometyx | $175 | $364,44015 claims |
| AstraZenecaTagrisso | $8,238 | $345,57119 claims |
| Bristol Myers SquibbRevlimid | $1,542 | $230,40213 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $908 | $167,625103 claims |
| Beigene USA, Inc.Brukinsa | $96 | $165,78311 claims |
| PfizerEliquis | $387 | $87,724113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 68 medical oncology providers in Georgia.
Other medical oncology in Macon
- Harry MooreMacon$20K
- Samir KhleifAugusta$337K
- Nabil SabaAtlanta$225K
- Sreekanth ReddyVidalia$116K
- Hagop YoussoufianDecatur$78K
- Suresh RamalingamAtlanta$75K
- Jonathan KaufmanAtlanta$73K
- Ragini KudchadkarAtlanta$69K
- Nisha JosephAtlanta$50K
- Eyal MeiriAtlanta$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.